Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
The results from the RELIEVE UCCD Phase 2b long-term extension study followed 130 patients who had originally responded to the drug during a 14-week induction phase.
After 44 weeks of maintenance therapy—totaling nearly 60 weeks of total exposure—the drug demonstrated what analysts are calling "unprecedented" durability for a TL1A inhibitor, a hot new class of autoimmune therapies.
The data showed a clear dose-dependent response across both primary forms of IBD.
In the Ulcerative Colitis (UC) cohort, 58% of patients on the high dose (900 mg) achieved clinical remission at week 44, compared to 47% on the lower dose.
In the Crohn’s Disease (CD) group, 55% of high-dose patients reached the primary endpoint of endoscopic response, a rigorous measure of internal healing.
Meanwhile, the drug’s safety profile remained consistent with earlier trials, with common side effects limited to mild respiratory infections and nasopharyngitis.